Business Description
JCR Pharmaceuticals Co Ltd
NAICS : 325412
SIC : 2834
ISIN : JP3701000006
Share Class Description:
TSE:4552: Ordinary SharesDescription
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.42 | |||||
| Debt-to-EBITDA | 3.08 | |||||
| Interest Coverage | 105.84 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 2.7 | |||||
| Beneish M-Score | -1.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.3 | |||||
| 3-Year EBITDA Growth Rate | 14.9 | |||||
| 3-Year EPS without NRI Growth Rate | 13.5 | |||||
| 3-Year Book Growth Rate | 16.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.15 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.32 | |||||
| 9-Day RSI | 39.55 | |||||
| 14-Day RSI | 38.6 | |||||
| 6-1 Month Momentum % | -23.08 | |||||
| 12-1 Month Momentum % | -40.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | |||||
| Quick Ratio | 1.15 | |||||
| Cash Ratio | 0.57 | |||||
| Days Inventory | 658.98 | |||||
| Days Sales Outstanding | 126.43 | |||||
| Days Payable | 49.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.46 | |||||
| Dividend Payout Ratio | 0.47 | |||||
| 3-Year Dividend Growth Rate | 35.7 | |||||
| Forward Dividend Yield % | 2.46 | |||||
| 5-Year Yield-on-Cost % | 9.67 | |||||
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | -2.65 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.83 | |||||
| Operating Margin % | 18.93 | |||||
| Net Margin % | 12.97 | |||||
| FCF Margin % | -33.99 | |||||
| ROE % | 9.96 | |||||
| ROA % | 5.48 | |||||
| ROIC % | 7 | |||||
| ROC (Joel Greenblatt) % | 15.91 | |||||
| ROCE % | 11.61 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.54 | |||||
| PE Ratio without NRI | 18.46 | |||||
| Shiller PE Ratio | 20.28 | |||||
| PEG Ratio | 0.96 | |||||
| PS Ratio | 2.41 | |||||
| PB Ratio | 1.78 | |||||
| Price-to-Tangible-Book | 1.9 | |||||
| EV-to-EBIT | 13.71 | |||||
| EV-to-Forward-EBIT | 18.7 | |||||
| EV-to-EBITDA | 13.71 | |||||
| EV-to-Forward-EBITDA | 15.14 | |||||
| EV-to-Revenue | 2.52 | |||||
| EV-to-Forward-Revenue | 3.95 | |||||
| EV-to-FCF | -7.29 | |||||
| Price-to-Projected-FCF | 3.67 | |||||
| Price-to-DCF (Earnings Based) | 0.39 | |||||
| Price-to-Median-PS-Value | 0.43 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.79 | |||||
| Price-to-Graham-Number | 1.25 | |||||
| Price-to-Net-Current-Asset-Value | 9.56 | |||||
| Earnings Yield (Greenblatt) % | 7.3 | |||||
| FCF Yield % | -14.2 | |||||
| Forward Rate of Return (Yacktman) % | 17.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JCR Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 41,365 | ||
| EPS (TTM) (円) | 42.76 | ||
| Beta | 0.26 | ||
| Volatility % | 42.92 | ||
| 14-Day RSI | 38.6 | ||
| 14-Day ATR (円) | 21.694999 | ||
| 20-Day SMA (円) | 812.25 | ||
| 12-1 Month Momentum % | -40.98 | ||
| 52-Week Range (円) | 778 - 1567 | ||
| Shares Outstanding (Mil) | 124.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
JCR Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
JCR Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price(円) | ||
|---|---|---|---|---|
| No Event Data | ||||
JCR Pharmaceuticals Co Ltd Frequently Asked Questions
What is JCR Pharmaceuticals Co Ltd(TSE:4552)'s stock price today?
The current price of TSE:4552 is 円793.00. The 52 week high of TSE:4552 is 円1567.00 and 52 week low is 円778.00.
When is next earnings date of JCR Pharmaceuticals Co Ltd(TSE:4552)?
The next earnings date of JCR Pharmaceuticals Co Ltd(TSE:4552) is .
Does JCR Pharmaceuticals Co Ltd(TSE:4552) pay dividends? If so, how much?
The Dividend Yield %  of JCR Pharmaceuticals Co Ltd(TSE:4552) is 2.46% (As of Today), Highest Dividend Payout Ratio of JCR Pharmaceuticals Co Ltd(TSE:4552) was 0.66. The lowest was 0.16. And the median was 0.37. The  Forward Dividend Yield % of JCR Pharmaceuticals Co Ltd(TSE:4552) is 2.46%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers